Tusk Therapeutics appoints Matthew Hall as Chief Financial Officer

London and Stevenage, UK – 14 September 2017: Tusk Therapeutics, an immuno-oncology company, is pleased to announce the appointment of Matthew Hall as Chief Financial Officer. Matthew is a seasoned finance professional with over 20 years’ corporate finance experience in a number of leading organisations and fast growing companies.  Most recently Chief Financial Officer at Simbec-Orion Group, Matthew has extensive … Read More

UCL’s Cancer Immunology group publishes on the relevance of CD25 as a target in cancer

London and Stevenage, UK Tusk Therapeutics, an immuno-oncology company, today announces that its collaborators, Dr. Sergio Quezada and Professor Karl Peggs of the Cancer Immunology group at University College London (UCL), published work in Immunity, a peer-reviewed medical journal, on targeting CD25 with an optimised antibody for the treatment of cancer. The paper entitled, Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T … Read More